ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1982 • ACR Convergence 2020

    Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus

    Josef Symon Concha1, Daisy Yan1, Christina Bax2, Adarsh Ravishankar3, Robert Borucki4, Rui Feng4 and Victoria Werth5, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2University of Pennsylvania, Department of Dermatology, Philadelphia, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 4University of Pennsylvania, Philadelphia, 5University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
  • Abstract Number: 0021 • ACR Convergence 2020

    Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned

    Dominique Kinnett-Hopkins1, Linda Ehrlich-Jones2, Holly Milaeger3, Alanna Kenney3, Lorena Rosiles3 and Rosalind Ramsey-Goldman4, 1Northwestern University, Chicago, IL, 2Shirley Ryan AbilityLab, Chicago, 3Northwestern University, Chicago, 4Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…
  • Abstract Number: 0253 • ACR Convergence 2020

    Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis

    Tara Tofighi1, Heather Reich2, Jiandong Su3 and Zahi Touma4, 1Department of Medicine, University of Toronto, Toronto, Canada, 2Division of Nephrology, University of Toronto, Toronto, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…
  • Abstract Number: 0270 • ACR Convergence 2020

    The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE

    Laura Whittall-Garcia1, Dafna Gladman2, Murray Urowitz3, Jiandong Su4 and Sindhu Johnson5, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…
  • Abstract Number: 0287 • ACR Convergence 2020

    RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells

    Xinghao Wang1, Philip Carlucci2, Jorge Romo-Tena1, Jose Torres-Ruiz1, Hong-Wei Sun1, Markus Hafner1, Mariana Kaplan3 and Luz Blanco4, 1NIAMS, National Institute of Health, Bethesda, 2New York University School of Medicine, New York, NY, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville

    Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…
  • Abstract Number: 0304 • ACR Convergence 2020

    Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids

    Wendy Dankers1, Melissa Northcott2, Taylah Bennett3, Brendan Russ3, Jacqueline Flynn1, Sarah Jones2 and Eric Morand1, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 3Department of Microbiology, Monash University, Melbourne, Australia

    Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
  • Abstract Number: 0521 • ACR Convergence 2020

    Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?

    Flavio Signorelli1, Gustavo Balbi2, Eloisa Bonfa3, Eduardo Borba4 and Danieli Andrade5, 1Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, 2Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, 3Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
  • Abstract Number: 0788 • ACR Convergence 2020

    Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery

    Wei Jiang1, Alexander Alekseyenko2, Gary Gilkeson3, Jim Oates4, Elizabeth Ogunrind5, Quan Li6, Diane Kamen2, Betty Tsao5 and Zhenwu Luo5, 1MUSC, Charleston, SC, 2Medical University of South Carolina, Charleston, SC, 3Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, SC, Charleston, SC, 5Medical University of South Carolina, Charleston, 6UT South Western Medical Center, Texas

    Background/Purpose: The mucosal microbiome contributes to disease pathogenesis via local and systemic interaction with the host. The hallmark of this interaction in the physiological condition…
  • Abstract Number: 0855 • ACR Convergence 2020

    Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study

    Richard Furie1, Samir Parikh2, Kenneth Harvey3, Christopher Kirk4, Darrin Bomba4 and MK Farmer5, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2The Ohio State University, Columbus, OH, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc, San Francisco, CA, 5Kezar, Raleigh, NC

    Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
  • Abstract Number: 0887 • ACR Convergence 2020

    Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network

    Simon Helfgott1, Jeremy Broestl2, Kent Kwas Huston3, Deepali Rane2, Jasvinder Singh4, Nehad Soloman5 and Colin Edgerton6, 1BWH- HMS, Boston, MA, 2Trio Health, Louisville, CO, 3Kansas City Physician Partners, Kansas City, MO, 4University of Alabama at Birmingham, Birmingham, AL, 5Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 6Articularis Healthcare, Summerville, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
  • Abstract Number: 0990 • ACR Convergence 2020

    Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors

    Jennifer Barnas1, Jennifer Albrecht1 and Jennifer Anolik1, 1University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells.  Type I interferon (IFN) are cytokines which…
  • Abstract Number: 1143 • ACR Convergence 2020

    The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus

    Priyatha Garlapati1, Jasmeen Uppal1, Sarwat Umer2 and Samina Hayat2, 1LSU Shreveport, Shreveport, 2LSU Shreveport, Shreveport, LA

    Background/Purpose: A large global survey released by the World Lupus Federation showed that the awareness of SLE is low and many individuals have never heard…
  • Abstract Number: 1270 • ACR Convergence 2020

    Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years

    Chi Chiu Mok1, Ling Yin Ho1, Kar Li Chan2, Sau Mei Tse2 and Chi Hung To3, 1Tuen Mun Hospital, Hong Kong, China (People's Republic), 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Pok Oi Hospital, Hong Kong, Hong Kong

    Background/Purpose: Background: Few studies of systemic lupus erythematosus (SLE) have a follow-up duration long enough to evaluate the time trend of survival, particularly in Asian…
  • Abstract Number: 1286 • ACR Convergence 2020

    Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity

    May Choi1, Emma Stevens2, Hongshu Guan2, Daniel Li3, Jack Ellrodt4, Benjamin Kargere4, Tianrun Cai2, Kazuki Yoshida5, Brendan Everett2 and Karen Costenbader6, 1Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital, Boston, MA, 3Harvard, Columbus, OH, 4Williams College, Williamstown, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
  • Abstract Number: 1302 • ACR Convergence 2020

    Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations

    April Jorge1, Zhiyao Wu2, Tashrif Chowdhury2 and Yijun Zhao2, 1Massachusetts General Hospital, Boston, MA, 2Fordham University, Computer and Information Sciences Department, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…
  • « Previous Page
  • 1
  • …
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology